140 related articles for article (PubMed ID: 38736011)
1. Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial.
Dai R; Deng C
World J Urol; 2024 May; 42(1):316. PubMed ID: 38736011
[No Abstract] [Full Text] [Related]
2. Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial.
Wada N; Mizunaga M; Abe N; Miyauchi K; Kobayashi S; Ohtani M; Tsunekawa R; Nagabuchi M; Morishita S; Ohyama T; Yamaguchi S; Iuchi H; Noda T; Saga Y; Motoya T; Kawakami N; Nishihara M; Numata A; Kakizaki H
World J Urol; 2024 Mar; 42(1):113. PubMed ID: 38431689
[TBL] [Abstract][Full Text] [Related]
3. Urinary incontinence: Patient-reported outcome measures favour use of mirabegron in patients with OAB.
Sidaway P
Nat Rev Urol; 2015 Nov; 12(11):593. PubMed ID: 26345211
[No Abstract] [Full Text] [Related]
4. Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study).
Torimoto K; Matsushita C; Yamada A; Goto D; Matsumoto Y; Hosokawa Y; Miyake M; Aoki K; Hirayama A; Tanaka N; Fujimoto K
Neurourol Urodyn; 2017 Apr; 36(4):1097-1103. PubMed ID: 27265880
[TBL] [Abstract][Full Text] [Related]
5. Drug therapy for an overactive bladder.
Thiagamoorthy G; Cardozo L; Srikrishna S
Womens Health (Lond); 2015 Jul; 11(4):445-8. PubMed ID: 26238677
[No Abstract] [Full Text] [Related]
6. Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: SYNERGY II study.
Alcántara Montero A
Actas Urol Esp (Engl Ed); 2019; 43(1):51-52. PubMed ID: 30025617
[No Abstract] [Full Text] [Related]
7. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
[TBL] [Abstract][Full Text] [Related]
8. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
9. Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB).
Rossanese M; Novara G; Challacombe B; Iannetti A; Dasgupta P; Ficarra V
BJU Int; 2015 Jan; 115(1):32-40. PubMed ID: 24602031
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
Wagg A; Cardozo L; Nitti VW; Castro-Diaz D; Auerbach S; Blauwet MB; Siddiqui E
Age Ageing; 2014 Sep; 43(5):666-75. PubMed ID: 24610862
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison.
Kennelly MJ; Rhodes T; Girman CJ; Thomas E; Shortino D; Mudd PN
Adv Ther; 2021 Nov; 38(11):5452-5464. PubMed ID: 34537953
[TBL] [Abstract][Full Text] [Related]
12. Mirabegron versus Solifenacin in Children with Overactive Bladder: Prospective Randomized Single-Blind Controlled Trial.
Soliman MG; El-Abd S; El-Gamal OM; Raheem AA; Abou-Ramadan AR; El-Abd AS
Urol Int; 2021; 105(11-12):1011-1017. PubMed ID: 34010843
[TBL] [Abstract][Full Text] [Related]
13. Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder?
Fogaing C; Mossa AH; Campeau L
Curr Urol Rep; 2020 Oct; 21(12):49. PubMed ID: 33090278
[TBL] [Abstract][Full Text] [Related]
14. N
Geoffrion R
J Obstet Gynaecol Can; 2017 Dec; 39(12):1230-1239. PubMed ID: 28986183
[No Abstract] [Full Text] [Related]
15. Vibegron (Gemtesa) for overactive bladder.
Med Lett Drugs Ther; 2021 May; 63(1623):67-69. PubMed ID: 33976098
[No Abstract] [Full Text] [Related]
16. Safety and efficacy of mirabegron in daily clinical practice: a prospective observational study.
Kallner HK; Christensson AA; Elmér C; Flam B; Altman D
Eur J Obstet Gynecol Reprod Biol; 2016 Aug; 203():167-72. PubMed ID: 27318184
[TBL] [Abstract][Full Text] [Related]
17. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
[TBL] [Abstract][Full Text] [Related]
19. Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study).
Nakagomi H; Mitsui T; Shimura H; Ihara T; Kira S; Sawada N; Takeda M
BMC Urol; 2022 Mar; 22(1):40. PubMed ID: 35313873
[TBL] [Abstract][Full Text] [Related]
20. Evaluating vibegron for the treatment of overactive bladder.
Rechberger T; Wróbel A
Expert Opin Pharmacother; 2021 Jan; 22(1):9-17. PubMed ID: 32993398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]